An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non muscle-invasive bladder cancer: Interim results

导出原文传递

翻译打印收藏纠错

作者： Packiam, Vignesh T. ^[1] ; Lamm, Donald L. ^[2] ; Barocas, Daniel A. ^[3] ; Trainer, Andrew ^[4] ; Fand, Benjamin ^[5] ; Davis, Ronald L., III ^[6] ; Clark, William ^[7] ; Kroeger, Michael ^[8] ; Dumbadze, Igor ^[9] ; Chamie, Karim ^[10] ; Kader, A. Karim ^[11] ; Curran, Dominic ^[12] ; Gutheil, John ^[13] ; Kuan, Arthur ; Yeung, Alex W. ; Steinberg, Gary D.

作者单位： Univ Chicago, Dept Surg, Urol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA ^[1] BCG Oncol PC, Phoenix, AZ USA ^[2] Cold Genesys Inc, Santa Ana, CA USA ^[3] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA ^[4] Premier Urol Grp LLC, Edison, NJ USA ^[5] Wake Forest Univ, Dept Urol, Winston Salem, NC 27109 USA ^[6] Alaska Urol Inst, Anchorage, AK USA ^[7] Univ Nebraska Med Ctr, Omaha, NE USA ^[8] Adult Pediat Urol & Urogynecol PC, Omaha, NE USA ^[9] Vanderbilt Univ, Dept Urol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA ^[10] Tri State Urol Serv, Cincinnati, OH USA ^[11] Univ Calif San Diego, Dept Urol, San Diego, CA 92103 USA ^[12] SciQuus Oncol, La Jolla, CA USA ^[13]

关键词 Non-muscle invasive bladder cancer Oncolytic adenovirus Intravesical therapy BCG unresponsive

发布时间 2019-09-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交